A new eradication resistance index as a predictor of metronidazole- containing second-line treatment of Helicobacter pylori

Digestion

Volumn 76, Issue 3-4, 2007, Pages 215-220

  Nishizawa, Toshihiro ^a   Suzuki, Hidekazu ^a   Masaoka, Tatsuhiro ^b   Iwasaki, Eisuke ^a   Hibi, Toshifumi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Life Extension Research Institute   (Japan)

Author keywords

13C urea breath test; Eradication therapy; Metronidazole resistance

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE; METRONIDAZOLE; PROTON PUMP INHIBITOR;

ACCURACY; ADULT; ARTICLE; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PREDICTOR VARIABLE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE; TREATMENT RESPONSE; UREA BREATH TEST;

AGED; AMOXICILLIN; ANTI-INFECTIVE AGENTS; BREATH TESTS; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; UREA;

EID: 40449141969     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000112649     Document Type: Article

References (24)

1. Matsuhisa T, Kawai T, Masaoka T, et al: Efficacy of metronidazole as second-line drug for the treatment of Helicobacter pylori infection in the Japanese population: a multicenter study in the Tokyo Metropolitan Area. Helicobacter 2006;11:152-158.
2. Suzuki H, Hibi T, Marshall BJ: Helicobacter pylori: present status and future prospects in Japan. J Gastroenterol 2007;42:1-15.
3. Asaka M, Sugiyama T, Kato M, et al: A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Helicobacter 2001;6:254-261.
4. Adamek RJ, Suerbaum S, Pfaffenbach B, Opferkuch W: Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin - influence on treatment outcome. Am J Gastroenterol 1998;93:386-389.
5. Murakami K, Sato R, Okimoto T, et al: Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance. Aliment Pharmacol Ther 2003;17:119-123.
6. 13C-urea breath test. Lancet 1987;1:1174-1177.
7. Perri F, Clemente R, Pastore M, et al: The 13C-urea breath test as a predictor of intragastric bacterial load and severity of Helicobacter pylori gastritis. Scand J Clin Lab Invest 1998;58:19-27.
8. 13Curea breath test to assess Helicobacter pylori bacterial load. Helicobacter 2005;10:615-619.
9. Lai YC, Yang JC, Huang SH: Pre-treatment urea breath test results predict the efficacy of Helicobacter pylori eradication therapy in patients with active duodenal ulcers. World J Gastroenterol 2004;10:991-994.
10. 13Carbon urea breath test for Helicobacter pylori: comparison with histology, culture, and ELISA serology. Gut 1991;32:1461-1464.
11. Masaoka T, Suzuki H, Kurabayashi K, Kamiya AG, Ishii H: Second-line treatment of Helicobacter pylori infection after dilution agar methods and PCR-RFLP analysis. Aliment Pharmacol Ther 2004;20(suppl 1):68-73.
12. National Committee for Clinical Laboratory Standards: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. Approved Standard ed 6, M7-A6. Villanova, National Committee for Clinical Laboratory Standards, 2004.
13. Nishizawa T, Suzuki H, Kurabayashi K, et al: Gatifloxacin resistance and mutations in gyra after unsuccessful Helicobacter pylori eradication in Japan. Antimicrob Agents Chemother 2006;50:1538-1540.
14. Miwa H, Nagahara A, Kurosawa A, et al: Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection? Aliment Pharmacol Ther 2003;17:1545-1551.
15. Masaoka T, Suzuki H, Kurabayashi K, et al: Could frameshift mutations in the frxA and rdxA genes of Helicobacter pylori be a marker for metronidazole resistance? Aliment Pharmacol Ther 2006;24(suppl 4):81-87.
16. Kutschke A, de Jonge BL: Compound efflux in Helicobacter pylori. Antimicrob Agents Chemother 2005;49:3009-3010.
17. Sisson G, Goodwin A, Raudonikiene A, et al: Enzymes associated with reductive activation and action of nitazoxanide, nitrofurans, and metronidazole in Helicobacter pylori. Antimicrob Agents Chemother 2002;46:2116-2123.
18. Narikawa S: Distribution of metronidazole susceptibility factors in obligate anaerobes. J Antimicrob Chemother 1986;18:565-574.
19. Maconi G, Parente F, Russo A, Vago L, Imbesi V, Bianchi Porro G: Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy? Am J Gastroenterol 2001;96:359-366.
20. Kobayashi D, Eishi Y, Ohkusa T, et al: Gastric mucosal density of Helicobacter pylori estimated by real-time PCR compared with results of urea breath test and histological grading. J Med Microbiol 2002;51:305-311.
21. Moshkowitz M, Konikoff FM, Peled Y, et al: High Helicobacter pylori numbers are associated with low eradication rate after triple therapy. Gut 1995;36:845-847.
22. Furuta T, Shirai N, Xiao F, et al: High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology 2003;50:2274-2278.
23. Nishizawa T, Suzuki H, Umezawa A, et al: Rapid detection of point mutations conferring resistance to fluoroquinolone in gyrA of Helicobacter pylori by allele-specific PCR. J Clin Microbiol 2007;45:303-305.
24. Sharara AI, Chaar HF, Aoun E, Abdul-Baki H, Araj GF, Kanj SS: Efficacy and safety of rabeprazole, amoxicillin, and gatifloxacin after treatment failure of initial Helicobacter pylori eradication. Helicobacter 2006;11:231-236.